» Articles » PMID: 15653685

HIV-1 Nef Disrupts Antigen Presentation Early in the Secretory Pathway

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2005 Jan 18
PMID 15653685
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Human immunodeficiency virus, type 1 Nef disrupts viral antigen presentation and promotes viral immune evasion from cytotoxic T lymphocytes. There is evidence that Nef acts early in the secretory pathway to redirect major histocompatibility complex class I (MHC-I) from the trans-Golgi network to the endolysosomal pathway. However, a competing model suggests that Nef acts much later by accelerating MHC-I turnover at the cell surface. Here we demonstrate that Nef targets early forms of MHC-I molecules in the endoplasmic reticulum by preferentially binding hypophosphorylated cytoplasmic tails. The Nef-MHC-I complex migrates normally into the Golgi apparatus but subsequently fails to arrive at the cell surface and become phosphorylated. Cell type-specific differences in the rate of MHC-I transport through the secretory pathway correlate with responsiveness to Nef and co-precipitation of adaptor protein 1 with the Nef.MHC-I complex. We propose that the assembly of a Nef.MHC-I.adaptor protein 1 complex early in the secretory pathway is important for Nef activity.

Citing Articles

Nef enhances HIV-1 replication and infectivity independently of SERINC5 in CEM T cells.

Ramirez P, Vollbrecht T, Acosta F, Suarez M, Angerstein A, Wallace J Virology. 2022; 578:154-162.

PMID: 36577173 PMC: 10484624. DOI: 10.1016/j.virol.2022.12.008.


Self-assembly and structure of a clathrin-independent AP-1:Arf1 tubular membrane coat.

Hooy R, Iwamoto Y, Tudorica D, Ren X, Hurley J Sci Adv. 2022; 8(42):eadd3914.

PMID: 36269825 PMC: 9586487. DOI: 10.1126/sciadv.add3914.


Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor.

Emert-Sedlak L, Shi H, Tice C, Chen L, Alvarado J, Shu S Viruses. 2022; 14(9).

PMID: 36146831 PMC: 9503669. DOI: 10.3390/v14092025.


Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Staudt R, Alvarado J, Emert-Sedlak L, Shi H, Shu S, Wales T J Biol Chem. 2020; 295(44):15158-15171.

PMID: 32862141 PMC: 7606690. DOI: 10.1074/jbc.REV120.012317.


Two Functional Variants of AP-1 Complexes Composed of either γ2 or γ1 Subunits Are Independently Required for Major Histocompatibility Complex Class I Downregulation by HIV-1 Nef.

Tavares L, de Carvalho J, Costa C, Silveira R, de Carvalho A, Donadi E J Virol. 2020; 94(7).

PMID: 31915283 PMC: 7081889. DOI: 10.1128/JVI.02039-19.